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Abstract: Targeting analgesic drugs for spinal delivery reflects the fact that while the conscious 
experience of pain is mediated supraspinally, input initiated by high intensity stimuli, tissue injury and/or 
nerve injury is encoded at the level of the spinal dorsal horn and this output informs the brain as to the 
peripheral environment. This encoding process is subject to strong upregulation resulting in hyperesthetic 
states and downregulation reducing the ongoing processing of nociceptive stimuli reversing the 
hyperesthesia and pain processing. The present review addresses the biology of spinal nociceptive 
processing as relevant to the effects of intrathecally-delivered drugs in altering pain processing following 
acute stimulation, tissue inflammation/injury and nerve injury. The review covers i) the major classes of 
spinal agents currently employed as intrathecal analgesics (opioid agonists, alpha 2 agonists; sodium 
channel blockers; calcium channel blockers; NMDA blockers; GABA A/B agonists; COX inhibitors; ii) 
ongoing developments in the pharmacology of spinal therapeutics focusing on less studied agents/targets 
(cholinesterase inhibition; Adenosine agonists; iii) novel intrathecal targeting methodologies including 
gene-based approaches (viral vectors, plasmids, interfering RNAs); antisense, and toxins (botulinum 
toxins; resniferatoxin, substance P Saporin); and iv) issues relevant to intrathecal drug delivery (neuraxial 
drug distribution), infusate delivery profile, drug dosing, formulation and principals involved in the 
preclinical evaluation of intrathecal drug safety. 
Keywords: Adenovirus transfection, dorsal horn, neurotoxins, pain pathways, spinal drug delivery, spinal analgesics, toxicity.  
RATIONALE 
 Targeting analgesic drugs for direct spinal delivery 
reflects the fact that while the conscious experience of pain 
is mediated supraspinally, input initiated by high intensity 
stimuli, tissue injury and/or nerve injury is encoded at 
the level of the spinal dorsal horn. Thus, high intensity 
(e.g., nociceptive) stimulation activates populations of 
small primary afferents, generating an intensity-dependent 
increase in activity of second order dorsal horn projection 
neurons. This excitation is transmitted through spinofugal 
projection pathways to higher centers, such as the 
somatosensory thalamus – somatosensory cortex, and to the 
medial thalamus - limbic cortices that are respectively 
believed to underlie the sensory-discriminative and affective-
motivational components of the pain experience [1-3]. The 
dorsal horn encoding process reflects a remarkable plasticity 
wherein the input-output function of the spinal dorsal horn is 
subject to pronounced regulation by local neuronal and non-
neuronal circuits as well as supraspinal (bulbospinal) input. 
Thus, following tissue or nerve injury there is an enhanced 
neuronal response to moderate or low intensity stimuli, e.g., 
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a right shift in the stimulus intensity-neuronal response 
curve. Accordingly, the spinal outflow generated by a given 
stimulus of moderate or low intensity following tissue and 
nerve injury generates an enhanced activation of supraspinal 
systems [4-6] and an enhanced pain state, e.g., hyperalgesia 
and allodynia [7], respectively. Accordingly, regulation of 
the spinal input-output function can alter the supraspinally 
organized pain experience. The organization of the input-
output function of the spinal dorsal horn and its associated 
pharmacology has been the subject of extensive investigation 
and review [8, 9]. The associated pharmacology of this 
processing as defined by studies of spinal physiology and 
behavior after spinal drug delivery has permitted targeting 
drugs at specific components to alter the content of the 
spinofugal transmission. While many analgesic drugs may be 
given systemically to exert their spinal action, the specific 
use of the intrathecal or epidural route for analgesic drug 
delivery may be employed for three reasons: i) the drug 
target lies at the spinal level (opiates, baclofen); ii) the agent 
does not penetrate the blood brain barrier (antisense, toxins); 
and/or iii) the agent penetrates the blood brain barrier but 
does so at systemic doses that produce undesirable side 
effects, so spinal delivery increases the therapeutic index 
(e.g., baclofen and opiates). 
 The efficacy of spinal drugs administered for the 
management of pain syndromes is dependent on the 
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the particular pain state. Pain states can be broadly 
categorized as those initiated by an acute noninjurious 
stimulus, those arising from tissue injury and inflammation 
and those secondary to nerve injury. Although the source of 
the pain state may be distinguishable, many clinical pain 
states likely reflect a combination of mechanisms; and, 
increasing evidence has pointed to overlapping components 
at the level of the primary afferent and spinal dorsal horn. 
These mechanisms and their associated pharmacology and 
biology have been extensively reviewed elsewhere [10, 11]. 
In this discussion we will focus on the lumbar intrathecal 
route of drug delivery and consider: i) ongoing developments 
in the pharmacology of spinal therapeutics focusing on 
agents/targets that have been employed and shown to a 
varying degree to have efficacy in humans, ii) novel 
targeting methodologies and iii) several issues relevant to 
intrathecal drug delivery. 
SPINAL THERAPEUTIC TARGETS 
 Spinal analgesic agents may target the primary afferent, 
the second order neurons, bulbospinal projections and non-
neuronal components. From a practical standpoint, many of 
these pharmacologic targets lie within the parenchyma of the 
dorsal horn and emphasize that after intrathecal delivery, the 
topically delivered agents (such as opiates, alpha2 agonists, 
targeted toxins, and transfection agents targeting 2
nd
 order 
neurons) must penetrate from the CSF through the pia and 
then up to several hundred microns in the parenchyma or 
more to reach these dorsal horn sites to exert their action. 
These issues will be discussed further below. In other cases, 
the agent may target the dorsal root ganglion cell (e.g., 
antisense, viral vectors). This target lies distal to the dural 
cuff formed by the meninges [12, 13] and is consistent with 
the fact that the DRG lies outside the blood brain barrier as 
evidenced by movement of large molecules into the DRG 
from the blood [14] and by the sympathetic innervation of 
the DRG vasculature [15]. The necessity to move from the 
CSF to the DRG for a drug to reach its effect site represents 
a barrier for spinally administered drugs. 
CURRENT SPINAL AGENTS 
 In this section, we will review families of agents that 
have been employed in humans for the management of 
spinal nociceptive processing. In each case we will consider 
the preclinical and clinical work with intrathecal delivery, 
mechanisms, typical molecules, adverse events with an 
emphasis on the work considering local drug toxicity and 
finally future areas of target and drug development. 
Opioids 
Spinal Opioids 
 Intrathecal delivery of opioids in amphibia and in 
mammals (from mouse to primate) [16, 17] reliably attenuate 
the response to noxious somatic and visceral stimuli that 
otherwise evoke an organized escape behavior with minimal 
effects upon light touch or proprioception [18]. 
Mechanisms of Action 
 Agonist action at the mu opioid receptor leads to 
hyperpolarization of neuronal membranes through activation 
of inwardly rectifying K+ channels and depression of 
excitatory neurotransmitter release from the presynaptic 
nerve terminal by blocking the opening of voltage sensitive 
Ca++ channels (VSCC), both of which serve to inhibit 
nociceptor neuronal activation [19]. Receptor autoradio- 
graphy and histochemistry has shown that mu binding and 
protein are limited to the substantia gelatinosa, the region in 
which small afferents show their principal termination, and 
to small, TRPPV1 (+) dorsal root ganglion cells [20, 21]. 
The presynaptic action blocking the opening of VSCCs leads 
to an inhibition of transmitter release from the nociceptive 
afferents and suppression of excitability in the second order 
neurons [17, 18]. Local delivery of opiates (delivered 
systemically in spinal transected animals, or by intrathecal, 
topical or iontophoretic methods) in the spinal cord 
selectively depresses discharge of spinal dorsal horn neurons 
activated by small (C high threshold) but not large (Aß low 
threshold) afferents [22-25] and blocks release of substance 
P from C polymodal nociceptors [26, 27]. At the spinal level µ 
opioids depress the bladder reflex arc, accounting for urinary 
retention [28]. Other effects such as sedation or depression 
of the CO2 response curve accounting for respiratory 
depression are mediated by a supraspinal action [29, 30]. 
Chronic spinal infusion of opiates in animal models shows 
clear loss of effect with continued exposure (e.g., tolerance) 
[31, 32], although the magnitude of this tolerance effect with 
continuous spinal infusion in man has been debated [33-36]. 
Drug Molecules 
 While morphine is the only FDA-approved drug for 
intrathecal administration, other opioids have been used for 
chronic intrathecal infusion including hydromorphone, 
methadone, and fentanyl/sufentanil [37]. With respect to 
neuraxial administration, the hydrophilic nature of morphine 
makes it a particularly useful drug for this route of 
administration as systemic uptake and thus potential side 
effects are delayed. As a comparison for these opioids, 
octanol/water partition co-efficients(cLogP) are morphine: 
0.9,hydromorphone: 1.6; Fentanyl: 3.8; Methadone; 4.0; 
Sufentanil: 4.2. In general higher cLogP values result in 
more rapid clearance from the intrathecal space (by 
meningeal and vascular uptake) and correspondingly shorter 
durations of action [38-40]. The hydrophilic nature of 
morphine accounts in part for its long residence time in the 
spinal space and for a comparatively long duration of action 
thereby making bolus drug delivery a useful means for 
intrathecal delivery. 
Adverse Events 
 Following intrathecal opiates, clinically significant 
sedation, altered mental status, nausea/vomiting, respiratory 
depression [41, 42] and these end points are considered to 
represent supraspinal mu opioid receptor activation [43]. 
Urinary retention is mediated by a spinal effect upon sacral 
mu receptors (e.g., produce by mu opiates and reversed by 
naloxone) of the bladder–spinal bladder reflex secondary to a 
suppression of small afferent input and increased external 
sphincter tone [44-46]. Pruritus can be mediated by a 
peripheral, nonopioid receptor mediated effect on mast cells 
degranulation (e.g., not naloxone reversible and with a 
minimal effect of agents such as fentanyl and sufentanil in 
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contrast to morphine and hydromorphone [47] and by an 
action upon mu receptors in a hypothesized brain stem site 
[48]. From a toxicological perspective, preclinical large 
animal safety studies have shown no significant effect upon 
spinal morphology, but has revealed the formation of 
intrathecal granulomas (e.g., an aseptic space-occupying 
mass proximal to the catheter tip composed of inflammatory 
cells that have migrated from the meninges) to be associated 
with the intrathecal infusion of high concentrations of 
morphine, hydromorphone and methadone, but not alfentanil 
or fentanyl) [49-55] but see [56]. Preclinical work has shown 
that in accord with the lack of an opiate structure activity 
relationship (e.g., granuloma inducing potency: morphine > 
fentanyl), the granuloma formation was not prevented by 
concurrent opiate receptor antagonism [54]. Preclinical work 
has pointed to the potential role of meningeal mast cell 
degranulation in granuloma formation [54]. In humans, 
comparable intrathecal masses have been observed after 
continuous infusion of high concentrations of most opioids 
including morphine and hydromorphone, but less so with 
fentanyl [53, 57]. 
Future Directions for Spinal Opiates 
 The pharmacodynamics of mu receptors has proven to be 
complex and suggest several promising avenues for future 
development: i) Mu opioid receptors occur as splice variants. 
Efforts have been made to develop ligands targeted at these 
splice variants [58, 59]. ii) Mu receptors couple through Gi/o 
protein in a ß arrestin dependent fashion such that ligand 
occupancy yields receptor internalization and desensitization 
of G protein signaling [60, 61]. Activation of mu receptors 
can be achieved separately from ß arrestin signaling. Such 
“G protein biased” ligands are believed to yield increased 
analgesic efficacy compared to other G protein-coupled 
receptors [62]. iv) Current work suggests that many G 
protein coupled receptors may form homo- and heterodimers 
[63]. Bivalent ligands interacting with these hetero-dimers, 
such as mu and delta receptors, have demonstrated enhanced 
cellular responses [64]. Thus, a mu agonist and a delta 
antagonist ligand display enhanced efficacy and a reduced 
propensity for tolerance [65]. Heterodimers constructed from 
opioid and nonopioid binding sites, such as bivalent Mu - 
CB1 (cannabinoid) [66] or µ-mGluR5 (metabotrophic 
glutamate receptors) [67, 68], have potent antihyperalgesic 
effects in avariety of models. v) Agents with delta opioid 
preference (e.g., the effects of which are antagonized by 
naloxone and naltrendole) have been shown to have a spinal 
analgesic action in preclinical models when given 
intrathecally as a bolus [69-74]; or an infusion [75, 76]. This 
work is consistent with the presence of delta opioid receptors 
presynaptic on subpopulations of small primary afferents 
which regulate the activity of thermal and/or mechanical 
nociceptor [77-79] and block of release of small spinal 
afferent peptides [26, 69, 80-82]. One agent administered 
intrathecally, DADL (d-ala2-d-leu5 enkephalin), was shown 
to have efficacy in humans [83, 84]. These agents have been 
shown to not display cross-tolerance to mu opiates [75, 76]. 
vi) As noted above, one current hypothesis regarding 
granuloma formation is that it may relate to a concentration 
dependent degranulation of mast cells that is not mediated by 
an opiate receptor [54]. This dissociation suggests the 
possibility that agents that do not result in mast cell 
degranulation at concentration necessary for opiate receptor 
activation and have intrathecal kinetics similar to morphine 
might provide an alternative approach to defining an 
alternative to the currently available opiates. Potential 
molecules might for example be potent mu or delta opioid 
peptides [85, 86]. 
Alpha 2 Agonists 
Spinal Alpha 2 Agonists 
 Alpha 2(α2) agonists administered intrathecally have 
been shown to have efficacy in a variety of animal pain 
models including those associated with acute tissue injury 
and neuropathic pain states [87, 88]. 
Mechanisms of Action 
 Three relevant subclasses of α 2agonists, α 2A, α 2B, α 2C, 
have been shown [89]. In situ studies have shown that 
subtype messages are present in sensory neurons: α2C, > α2A, 
>> α2B, whereas in spinal dorsal horn the message levels are: 
α2B> α 2c> α 2A [90]. Interestingly, discrepancies are noted 
between the α2 subtypes as defined by message and immuno- 
histochemistry (see [91]). Spinal α2adrenergic receptors display 
several characteristics: i) binding is present presynaptically 
on C-fibers and postsynaptically on spinal neurons; ii) 
agonists are believed to alter spinal nociceptive processing 
by preventing opening of voltage-sensitive Ca channels 
(blocking release) [92, 93] and increasing potassium conductance 
leading to hyperpolarization of dorsal horn neurons through 
increased pK conductance [87, 88, 94, 95]. Consistent with 
their pharmacology, the analgesic activity is reversed by 
α2antagonists such as atipamezole [96-98]. At the spinal 
level, α 2 agonists reduce preganglionic sympathetic outflow, 
accounting in part for their hypotensive actions, while 
sedation is mediated supraspinally [99]. A similar mechanism 
of action to opioids is noted, albeit through distinctly 
different receptors that are often co-localized. Tolerance with 
repeated exposure has been reported, but cross-tolerance 
with mu opioids does not occur [100, 101]. 
Drug Molecules 
 Dexmedetomidine, clonidine, and xylazine are α2 
agonists used systemically in human and veterinary clinical 
practice, however, clonidine is the only α 2agonistwith FDA 
approval for spinal (epidural) delivery in humans. Perhaps 
not surprisingly, the addition of clonidine to neuraxial 
morphine enhances analgesic efficacy [102, 103]. 
Adverse Events 
 The use of α2 agonists such as clonidine is largely limited 
by sedation, systemic hypotension, and bradycardia that are 
likely produced by a central sympatholytic effect and 
activation of α2A in the medulla. Chronic epidural [104] and 
limited intrathecal large animal [49] preclinical safety work 
has shown no evidenceof spinal toxicity. 
Future Directions for Spinal Alpha 2 Agonist 
 While some work has suggested that analgesia and 
sedation may be separable if different sub-classes of α 2 
receptors can be targeted [98, 105, 106], such differentiation 
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is not supported by studies in gene-altered mice [107], and 
the work has not led to definitively distinguishable agents. 
The cLogP of clonidine (2.6) and dexmedetomidine (3.0) 
reflect upon the short duration of action and rapid systemic 
exposure that occurs with these spinal agents suggesting that 
a more polar α2agonist might have virtue. 
Spinal Sodium Channel Blockers 
Spinal Antagonists 
 The original drugs employed for spinally directed therapy 
were cocaine and derivatives [108, 109]. Those incredibly 
insightful studies performed over 100 years ago defined the 
potent anesthetic and motor block produced by intrathecal 
cocaine and the residual presence of analgesia to pain and 
temperature [110]. Preclinical studies have typically shown 
minimal effects upon acute nociception at sub-motor 
impairing doses of conventional sodium channel blockers 
given intrathecally. However, they are reported to reliably 
result in a remarkable analgesic synergy with intrathecal 
agents such as opiates or alpha 2 agonists with minimal 
attendant effects upon motor function in animal models 
[111-114] and in humans [115-117]. There is a clinical 
literature that suggests that neuraxial local anesthetics may 
display a tachyphylaxis with chronic exposure that may 
respond to different local anesthetics [118]. However, 
systematic clinical evidence of this impression is 
controversial (see [119]. Nerve block studies do not display 
such changes, suggesting that if tachyphylaxis does occur it 
reflects some system level change [120]. 
Mechanisms of Action 
 The common mechanism of all clinically employed 
“local anesthetics” is to block the voltage-gated sodium 
channel (Nav). Navs consist of an α -subunit complex that 
forms the transmembrane spanning pore and auxiliary β -
subunits [121]. The channel expresses molecular components 
mediating the voltage sensing and gating elements that result 
in the voltage-dependent opening and voltage-independent 
closing of the channel. Importantly, the typical anesthetic 
with pKa >7.4 is unionized at extracellular physiological 
pHs, penetrates the membrane, reionizes in the more acidic 
intracellular environment and in the ionized (protonated) 
state blocks the channel from the intracellular side. Several 
general properties of the block are appreciated. The 
differential block of motor axons and low vs. high threshold 
sensory afferents reflect the greater sensitivity of small vs. 
large afferents to block of the conducted action potential. As 
local anesthetics bind to sodium channels in an activated 
state, the initiation of blockade is facilitated in neurons 
discharging at a high frequency (e.g. a state-dependent block 
[122-124]. Previous speculations [112] have pointed to the 
role of impedance mismatching at the extensive afferent 
branch points within the dorsal horn. This would lead to an 
increased probability of conduction failure in the small (C-
fiber) afferents [125] and an increased susceptibility of the 
terminal depolarization to be blocked by low concentrations 
of local anesthetics. 
 Nine isoforms have been identified with distinguishable 
activation properties and tissue distributions [126]. Of  
 
particular note, Nav1.4 and Nav1.5 are present in skeletal and 
cardiac myocytes. Nav1.7, Nav1.8, and Nav1.9 are 
predominantly expressed in small sensory DRGs/afferents, 
while NaV 1.1 and 1.6 are found more highly expressed in 
large DRG/axons [127]. Clinically employed local 
anesthetics (amide and ester) are essentially non-selective in 
their blocking of different sodium channels (see [124]). 
Several sodium channel isoforms are sensitive to the puffer 
fish toxin, tetrodotoxin (TTX) (Nav1.1, Nav1.2, Nav1.3, 
Nav1.4, Nav1.6, and Nav1.7), while others (Nav1.5, Nav1.8, 
and Nav1.9) are resistant to TTX [124, 128]. Importantly, 
following chronic inflammation and peripheral nerve injury, 
prominent increases in the expression of small afferent Navs 
has been noted and such increases appear to be associated 
with the initiation of ongoing (ectopic) afferent traffic [129]. 
The use of antisense, siRNA and murine mutations  
have indicated that impairment of Nav1.3, 1.7,1.8 and 1.9 
expression has varying antihyperpathic effects in models of 
inflammatory and neuropathic pain states [127, 130, 131]. 
Specific gain and loss of function mutations in the Nav1.7 
channels have been identified in humans wherein there is an 
increased and decreased pain state, respectively [132, 133]. 
Drug Molecules 
 Avariety of local anesthetics are employed with two 
common structural motifs: Hydrophobic (aromatic residue) 
and hydrophilic (tertiary or secondary amines) domains 
separated by an ester procaine, 2-chlorprocaine, tetracaine) 
or amide (lidocaine, bupivacaine, ropivacaine) linkage. The 
principal differences between drugs being use dependency, 
effective concentrations and duration of action. Though 
differences in relative potency with respect to blocking 
different Nav subtypes have been reported, such selectivity 
remains controversial and in part reflect variation in on and 
off rates of binding and channel opening and inactivation 
properties rather than a specific difference in Nav affinity 
[123, 124]. The properties of local anesthetic actions at the 
channel have been extensively reviewed elsewhere [134, 
135]. 
Adverse Events 
 Adverse events such as motor weakness and anesthesia 
after intrathecal delivery of currently employed local 
anesthetics reflect side effects related to the block of the 
several voltage-gated channels associated with large sensory 
and motor axons and spread of the block to higher centers 
(e.g. “total spinals”) and to non-neuraxial tissues such as 
cardiac myocytes. As noted, the large axons are relatively 
resistant to conduction block. Neurological signs secondary 
to intrathecal local anesthetics have been identified in 
patients with uncomplicated spinal anesthesia wherein distal 
lower extremity pain was reported. Transient neurologic 
symptoms were reported with relative risk being higher for 
lidocaine compared to bupivacaine, prilocaine, procaine and 
mepivacaine [136]. Preclinical safety evaluations with 
intrathecal local anesthetics such as lidocaine, bupivacaine 
and ropivacaine have been marked initially by mitochondrial 
vacuolization, mild focal edema, with evidence of change in 
the lamellar structure of fibers and Schwann cells in rat and 
dog models [137, 138]. The molecular mechanisms of the  
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local anesthetic toxicity are not understood. Work with 
intrathecal TTX has shown that long-lasting sodium channel 
block itself is not associated with a specific toxicity [139]. 
Small local anesthetic molecules can have effects on lipid 
membrane components, which reflect the detergent nature of 
these amphiphillic molecules [140]. Though the mechanisms 
are not understood, the afferent toxicity does appear to be 
associated with increased intracellular calcium in the DRG 
[141]. 
Future Directions for Spinal Sodium Channel Blockers 
 The current advances in our understanding of the Nav 
subtypes and their differential distribution in the body and 
particularly in the neuraxis, as well as the upregulation in 
their expression after injury leading to ectopic activity and 
increased neuronal excitability, offers evident opportunities 
for creating drugs that target those elements that might be 
most altered by the pain states. Several strategies have been 
employed. As reviewed elsewhere, there has been a great 
deal of effort to define structures that prefer one channel 
over another [142, 143]. Preclinical work with intrathecally-
delivered molecules targeted at Nav1.7 [144] and 1.8 [145] 
has shown preclinical efficacy. While much attention has 
been paid to the TTX-resistant sodium channels in sensory 
neurons (e.g., Nav1.8 and 1.9) an important role for TTX 
sensitive channels cannot be excluded. Intrathecal TTX has 
been reported to have mild effects upon acute and 
inflammatory nociceptive end points [146]. Nav1.3 and 1.7 
produce TTX-sensitive sodium currents and have been 
shown to contribute to ectopic firing in injured neurons. As 
noted above, Nav1.3 expression increases with nerve injury. 
Intrathecal knockdown of these channels with antisense 
reduced their upregulation in nerve injury and reduced the 
behaviorally defined tactile allodynia [147-149]. The use of 
intrathecally-delivered siRNA and antisense targeting these 
structures clearly offers a direct approach to targeting these 
membrane proteins [127, 130, 131]. An alternate strategy for 
selective targeting has been the use of non-selective blockers 
that are restricted in terms of the cells to which they have 
access. The quaternary lidocaine molecule (QX314) cannot 
readily penetrate the cell. However, activating membrane 
channels such as the TRV1 channel has been reported to 
allow QX314 entry into the neurons and to block the Nav 
channel from the interior and result in a selective block of 
the TRPV1 expressing primary afferent [150]. Intrathecal 
QX316 has been reported to produce significant pain 
behavior after intrathecal delivery in rodent models and this 
may reflect upon its ability to concurrently activate the 
TRPV1 channel [151]. It should be noted that while this 
section considers the role of sodium channel blockage in 
reducing axon excitability, it has been shown that conditions 
leading to an enhanced expression of sodium channels often 
lead to a reduction in the expression of potassium channels 
which further contributes to membrane excitability [152]. 
Increasing potassium conductance with potassium channel 
agonists or increasing the expression of potassium channels 
can serve to move the membrane towards a hyperpolarized 
state and normalize (reduce) otherwise enhanced axon, DRG 
and terminal excitability, an action associated with an 
antihyperalgesic action [153, 154]. 
Spinal Calcium Channel Blockers 
Spinal Antagonists 
 Ziconotide (Prialt), discovered in the venom of fish-
killing marine snails [155], was demonstrated to be a potent 
antihyperpathic agent in rodents and humans after intrathecal 
delivery as a bolus or an infusion [156-159]. Ziconotide was 
observed to be a highly selective ligand blocking the N-type 
voltage-sensitive calcium channel (VSCC) [160]. 
Mechanisms of Action 
 VSCCs facilitate neurochemical cell signaling through 
mobilization of presynaptic vesicles for neurotransmitter 
release. The N-type calcium channel is most important for 
neurotransmission in sensory neurons. This calcium channel 
subtype is densely expressed in presynaptic nerve terminals 
in the spinal cord superficial dorsal horn and dorsal root 
ganglia. In the presence of nerve injury these channels are 
upregulated [161] and blocking these channels has shown to 
produce antinociceptive effects [162] that do not show 
tachyphylaxis (tolerance) [163]. 
Drug Molecules 
 Ziconotide, an ω-conotoxin derived from the cone snail, 
is a calcium channel blocker that binds with high affinity and 
physically blocks the N-type calcium channel. It is a stable, 
water soluble, large 25 amino acid, polybasic peptide 
containing three disulfide bridges with a molecular weight of 
2639 Da. Ziconotide is FDA approved for intrathecal use for 
chronic, severe pain. 
Adverse Events 
 In animals, ziconotide produces dose-dependent body 
shaking and ataxia [157, 164, 165]. A narrow therapeutic 
index reflecting nonspinally mediated side effects such as 
dizziness, nausea and somnolence has limited the human 
clinical utility of ziconotide. Extensive large animal 
preclinical safety evaluations have emphasized the lack of 
tissue toxicity of this molecule at clinically useful 
concentrations [166]. 
Future Directions for Spinal Calcium Channel Blockers 
 i) Currently the only N type channel blocker approved as 
a therapeutic is Ziconotide. Considerable work has focused 
on the development of other conopeptides as well as small 
molecules [160, 167]. Alternatively, there is considerable 
interest in altering N-type VSCC function by impeding its 
membrane trafficking and such strategies have been shown 
to alter nociceptive processing [168]; ii) VSCCs are broadly 
divided into two types: high-voltage-activated (HVA) and 
low-voltage-activated (LVA) channels. HVA channels are 
further divided into L-, P/Q-, N- and R-type channels. LVA 
channel include the T-type channel. Each channel locates in 
a distinct area in the peripheral nerve and CNS and 
contributes in different ways to nociceptive transmission (see 
[169]). Spinal blockade of R- and T-type but not L and P/Q 
type VSCCs attenuated formalin-induced pain behavior 
[170-172]. In other work, intrathecal PQ-preferring toxins 
displayed efficacy in neuropathic pain models [173]. 
Intrathecal delivery of T-type calcium channel blockers  
 
Current and Future Issues in the Development of Spinal Agents Current Neuropharmacology, 2017, Vol. 15, No. 2    237 
(ethosuximide and mibefradil)produce analgesia in rodents 
[171, 174]. iii) An alternate therapeutic target thought to 
involve regulation of VSCCs is the α2 delta calcium channel 
auxiliary subunit. This subunit is the binding site for 
gabapentinoid drugs in the dorsal horn. In preclinical 
models, gabapentin and pregabelin have been shown to have 
potent effect in a variety ofhyperalgesic pain [175-178] 
Preclinical results indicate adequate spinal pK with a very 
hydrophilic cLogP (-1.13). In a recent study, however, it was 
unexpectedly reported that intrathecal infusion of gabapentin 
failed to alter pain assessments in human patients suffering 
from a variety of neuropathic and non-neuropathic pain 
states [179]. 
NMDA Ionophores 
Spinal NMDA Antagonists 
 A wide variety of NMDA ionophore antagonists given 
intrathecally have been reliably shown to have potent 
attenuating effects upon the hyperpathia resulting from a 
variety of tissue [99, 180] and nerve injury [181] facilitated 
pain states in animals and, though not approved, in humans 
[182]. 
Mechanisms of Action 
 The NMDA receptors are heteromeric protein complexes 
assembled from three families of NMDA receptor subunits 
(NR1, NR2 and NR3) each with multiple distinct subunits 
[181]. When activated it allows the influx of sodium, 
potassium and calcium. Glutamate, released from afferents 
and interneurons in response to high threshold noxious input 
from C fibers, binds target sites on the NMDA receptor. 
These receptors are densely expressed in spinal cord dorsal 
horn on the terminals of the primary afferent, on second order 
neurons as well as in non-neural cells such as astrocytes and 
oligodendroglia. Activation of the channel requires the 
presence of occupied binding sites on the ionophore for 
glycine and polyamines [183]. At resting membrane potentials 
a Mg++ ion provides a block in the channel that effectively 
prevents calcium flux through the channel. In the face of 
repetitive activation, the membrane displays progressive 
depolarization, relieves the Mg++ block and allows calcium 
flux [183], leading to a cascade initially described electro- 
physiologically, as wind-up [184]. Blocking NMDARs inhibits 
the wind-up phenomenon of spinal dorsal horn neurons [185, 
186]. This increased excitability further results in activation 
of a variety of protein kinases (Mitogen activated kinases 
and PKA and PKC) which, respectively, increases protein 
synthesis, phosphorylates channel and enzymes that lower 
their thresholds for activation and enhances their ion 
permeability leading to hyperalgesic states [187-190]. 
Drug Molecules 
 Numerous NMDA antagonists have been employed for 
preclinical work showing the antihyperpathic effects of 
intrathecal NMDA antagonists [191-194]. These include 
channel blockers such as ketamine (cLogP: 3.1), MK-801 
(cLogP: 2.7) and memantine (cLogP 2.0), and competitive 
antagonists such as 2 amino 5 phosphonovalorate (cLogP=-2.32), 
glycine site blockers such as 7 Chlorothiokynurenic acid 
(cLogP: 2.7). No NMDA antagonists have been approved for 
human neuraxial use. 
Adverse Events 
 Single intrathecal injections of ketamine did not produce 
histological alterations in the dog [195] but resulted in spinal 
cell death in the neonatal rat [196]. After repeated intrathecal 
delivery in rabbits [197] or continuous infusion in dogs 
[198], Ketamine and a number of other NMDA channel-
blocking antagonists including MK-801, dextrorphan, 
dextromethorphan and memantine and the nonopiate agent 
D-methadone, and to a lesser degree the glutamate antagonist 
2AP5,resulted in prominent spinal pathology reflecting 
parenchymal necrosis in dogs and/or sheep [198, 199]. These 
spinal effects, where examined, appear to be concentration-
dependent and, with the exception of the neonatal model, the 
therapeutic ratio (e.g., therapeutic dose/minimum toxicity 
dose-concentration) has not been defined. It should be noted 
that a weakness of these studies is that there was no 
corresponding assessment of the efficacy of the intrathecal 
infusion was assessed relative to the dose required to 
produce pathology in these animals models (but see [196]). 
Future Directions for Spinal NMDA Antagonists 
 i) Preclinical work and anecdotal clinical data clearly 
indicate the efficacy of spinal NMDA antagonism. However, 
in light of the controversy related to the intrathecal toxicity 
of NMDA antagonists (see above), characterization of the 
intrathecal therapeutic ratio for the NMDA antagonist is 
necessary to define the relative safety of these agents. While 
their ability to produce untoward histopathology is evident, it 
is not clear how close the toxicity is in the adult, 
continuously infused animal to the dose-producing beneficial 
consequences. ii) The NMDA ionophore is constituted of a 
variety of subunits. Ionophores constituted of different 
subunits have different binding profiles and are differentially 
distributed [200, 201]. One such subtype is the NR2B 
subunit. Specific antagonists such as Ifenprodil [202], Ro 25-
6981 [202, 203] and Conantokin G [204] has antihyperpathic 
effects in models of spinal injury and facilitated processing. 
Other NMDA ionophore-associated targets for which ligands 
have been shown to produce analgesia include the glycine 
binding site and the polyamine binding site [201, 205]; iii) 
Magnesium sulphate is a noncompetitive antagonist of the N-
methyl-d-aspartate (NMDA) receptor and thus can modify 
nociceptive modulation [206-207]. Limited preclinical safety 
studies have been performed examine the effects of bolus 
delivery in several species. At least one preclinical paper has 
reported evidence of neurotoxicity after intrathecal delivery 
[208]. Chronic spinal exposures have not been examined. A 
variety of reports have noted activity in humans after 
intrathecal and epidural delivery [209]. iv) Agmatine is an 
endogenous neuromodulator present in the brain and spinal 
cord that has both NMDA receptor antagonist and nitric 
oxide synthase inhibitor activities. It has been reported to 
have antihyperalgesic properties after systemic and 
intrathecal delivery [210]. v) The primary focus of glutamate 
ionotrophic receptors has been on the NMDA. However, the 
AMPA receptor plays a prominent role in acute dorsal horn 
evoked excitation as a sodium selective ionophore [211].  
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Agents such as Tezampanil (LY-293558, NGX-424) given 
spinally in preclinical studies has effect upon postoperative 
pain and spasticity [212, 213] and its action were associated 
with changes in motor function, a fact consistent with the 
prominent role of AMPA in motor neuron excitation. In 
humans oral dosing has indicated some effects upon afferent 
evoked hyperalgesia [214]. vi) The AMPA receptor is 
composed of GluR1-GluR4 subunits. In the face of injury, 
there is a change in subunit trafficking and ionophore 
composition such that the ionophore becomes calcium 
permeable. Intrathecal antagonists selective for the calcium 
permeable AMPA site, such as joro spider toxin, reduces the 
development of secondary mechanical allodynia evoked in 
tissue injury models [215-216]. 
GABA-A 
Spinal GABA-A Activation 
 Preclinically, intrathecal GABA-A agonists such as 
muscimol or isoguavacine have been reported to display 
efficacy in neuropathic pain models [217-221]. Intrathecal 
benzodiazepines and neurosteroids have been shown 
precliincally in rodent models to attenuate tissue and nerve 
injury hyperpathic states [218, 222-226]. In dogs, intrathecal 
benzodiazepines have been shown to depress nociceptive 
reflexes [227]. In humans, bolus intrathecal Midazolam was 
reported to display efficacy after bolus deliveryin 
postoperative, low back and labor pain [228-231]. 
Mechanisms of Action 
 The GABA-A receptor is a GABA gated chloride 
ionophore composed of five subunits, each with four 
transmembrane spanning domains. With multiple subunits, 
not surprisingly, several different pharmacological and 
functional phenotypes of the receptor have been identified 
[232]. GABA binds at an α and a β subunit [233] to activate 
the Cl conductance. Importantly, numerous agents interact 
with specific sites on the GABA-A ionophore to serve as 
positive allosteric modulators. Thus, benzodiazepines (e.g., 
midazolam, diazepam) bind to specific populations of 
GABA-A ionophores that possess both an α and a γ subunit. 
This binding forces a conformation where GABA displays a 
higher affinity increasing the frequency of opening of the ion 
channel [234]. Similarly, several neurosteroids such as 
allopregnanolone will bind to the GABA-A ionophore and 
force conformational changes enhancing GABA effects 
[235, 236]. Immunohistochemical studies have shown dense 
staining in spinal Rexed laminae for several alpha, beta and 
gamma subunits likely corresponding to primary afferents 
[237, 238] presumably localized on primary afferent 
terminals. Electrophysiological studies have indeed shown 
GABA-A receptors to be present on both large and small 
afferents [239] and such studies have emphasized the potent 
regulation by benzodiazepines of the excitability of small, 
nociceptive, primary afferents through their associated 
GABA-A receptors [240]. There is not enough space here to 
review the differential distribution of functionally distinct 
GABA-A receptor phenotypes, but electrophysiological and 
knockout studies have shown considerable phenotype 
diversity in the neuraxis [241, 242]. 
 
Drug Molecules 
 As noted above, the common agonists employed in 
pharmacological studies of the GABA-A receptor are muscimol 
(cLogP = -0.7). Agents serving as allosteric modulators 
include benzodiazepines (midazolam; cLogP = 3.16) and 
neurosteroids (allopregnanolone; cLogP= 3.7). 
Adverse Events 
 Activation of nonspinal GABA-A ionophores has 
prominent sedative, anxiolytic and amnestic effects. At the 
spinal level enhanced GABA-Aactivity has been shown to 
have effects upon motor function [243]. The use of 
intrathecal midazolam in man has been reported as noted 
above. However, there has been concern about the potential 
for spinal toxicity [243, 244]. While several systematic 
assessments of toxicity have shown distinct deleterious 
reactions [245, 246], others have failed to observed toxicity 
[56]. The origin of the preclinical toxicity is not known, but 
the acidic pH required by the formulation of midazolam may 
be a contributing issue (see for review [244]. In our opinion, 
concern over its potential for toxicity remains. Barbiturates 
act through the GABA A ionophore, but their spinal action 
may be associated with a cauda equine syndrome. Such has 
been the case after inadvertent intrathecal injection of 
sodium thiopental [247]. 
Future Directions for Spinal GABA-A Agonists 
 As noted above, a high degree of heterogeneity of the 
GABA-A receptor structure/subtype has been observed, 
which raises the possibility of defining specific structures 
targeting these subtypes [242, 248-250]. Activation of spinal 
GABA-A ionophores either directly through agonist 
activation or by positive allosteric modulators has significant 
preclinical support for further development as reviewed 
above with benzodiazepines and neurosteroids. Interestingly 
agent such as Etifoxine may act by stimulating 
allopregnanolone synthesis in the spinal cord [251]. Current 
work has shown that subtype specificity may be achieved 
and that they may have different effects upon neuronal 
inhibition in different systems [252]. 
GABA-B Receptors 
Spinal GABA-B Agonists 
 Baclofen, the clinically approved GABA-B agonist, has 
potent stereospecific suppressive effects upon motor tone 
[253] and is widely used clinically to regulate motor tone in 
the case of spasticity [254-256]; but it has also been 
implicated in having suppressive effects upon nociceptive 
processing after intrathecal delivery in preclinical models of 
facilitated processing [217] and hyperpathia in mono and 
polyneuropathies and spinal injury [220-221, 257-259] and 
in humans [260, 261]. 
Mechanisms of Action 
 The GABA-B receptor is a metabotrophic receptor 
coupled to intracellular signaling through Gi and Go proteins 
that, when stimulated, activate K+ and inhibit Ca2+ channels 
via the βγ complex, with the α subunit regulating adenylate  
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cyclase [262]. They are dense in laminae I and II in the 
dorsal horn on small afferent terminals and on 2
nd
 order 
neurons [263]. DRG neurons of various diameters also 
express GABA-B immunoreactivity. At the electron 
microscopic level, the immunoreactivity is present on 
myelinated and unmyelinated fibers and on the dendrites of 
dorsal horn neurons. Electrophysiological studies show that 
GABA-B agonists initiate hyperpolarization through an 
increase in K conductance through G protein coupling and 
attenuation of evoked primary afferent transmitter release 
through block of opening of voltage gated Ca channels. 
GABA-B receptors are present on motor neurons and serve 
to reduce their excitability leading to flaccidity at doses that 
are similar to those yielding antinociception. 
Drug Molecules 
 The common GABA-B agonist is baclofen (cLogP = 1.3), 
which exerts its effects in a stereospecific fashion [253, 264]. 
GABA-B selective antagonists, such as saclofen [265], block 
the effects of these agents. 
Adverse Events 
 Intrathecal baclofen produces a prominent dose-
dependent motor weakness in animal models and humans 
[253]. In humans, this effect has a particular therapeutic 
benefit in managing clinically relevant spasticity (see [256]). 
Intrathecal baclofen has undergone one published systematic 
toxicology evaluation in dogs involving a 28-day continuous 
infusion without evidence of toxicity [55, 266]. Intrathecal 
baclofen has been reported to result in intrathecal space-
occupying masses, but this has proven to be controversial 
[267, 268]. 
Future Directions for GABA-B Receptor Targeting 
 Other GABA-B agonists have been identified and include 
agents such asCGP35024 and the more potent CGP 44532, 
which were reported to induce antinociceptive responses at 
doses below those that cause sedation [257, 269]. It has 
become clear that regulation of GABA-B activity is 
associated with a role for positive allosteric modulators to 
potentially reduce unwanted drug effects. These agents 
interact with discrete domains of the GABA-B receptor 
stabilizing it in the active state involved in G-protein 
coupling. Such agents have been found to modulate the 
GABA-B receptor analgesic activity [270]. 
Spinal Cholinesterase Inhibitors 
Spinal Cholinesterase Inhibitors 
 Neostigmine is a cholinesterase inhibitor that yields 
antinociceptive effects in a variety of preclinical models 
[106, 271-275] in several species such as rodents and sheep 
[276]. Bolus intrathecal delivery of neostigmine has been 
reported in humans to have significant effects upon 
postoperative pain [277-279]. 
Mechanisms 
 Intrathecal cholinesterase inhibitors are considered to 
increase the local extracellular levels of acetylcholine. Spinal 
delivery of a variety of cholinergic antagonists has indicated 
the importance of muscarinic receptors and in particular 
several M subtypes in mediating these antinociceptive 
actions [280]. These findings are consistent with the 
antinociceptive effects of intrathecal muscarinic agonists 
[281]. Spinal muscarinic receptors in the spinal cord are 
strongly expressed in the superficial dorsal horn [282].There 
are five subtypes (M1-5) [283, 284] divided into two broad 
groups: M1/M3/M5 coupled to Gq/11 proteins, activating 
phospholipase C - IP3—diacylglycerol (DAG) cascade 
yielding increased Ca
2+ 
and activation of protein kinase C 
and mitogen-activated protein kinases. M2 and M4 receptors 
(M2-class) coupling to Gi/o proteins and inhibiting opening 
of voltage-gated calcium channels [284]. M1/3/5 receptors 
induce membrane depolarization by enhancing cation 
currents and inhibiting potassium channels [285, 286], while 
M2 and M4 channels activate potassium channels and inhibit 
some voltage-gated Ca channels (especially Cav2.2), leading 
to hyperpolarization and block of transmitter release [287]. 
M2 and M4 knockout animals show a robust attenuation of 
the analgesic effects produced by muscarinic agonists [165, 
288, 289] Interestingly, stimulation of M2 and M4 receptors 
inhibit spinal glycinergic function which might lead to a 
paradoxical hyperpathia, whereas stimulation of the M3 
activation potentiates synaptic glycine release [290]. The 
events underlying the effects upon spinal nociceptive 
processing have been proposed to reflect several 
mechanisms.1) effect of muscarinic receptor subtypes in 
reducing afferent terminal excitability (reducing glutamate 
release) [289]; and, 2) activation of muscarinic receptors on 
glycinergic and GABAergic interneurons enhancing dorsal 
horn inhibitory amino acid release through muscarinic 
subtypes, such as the M2 and M4 receptors [290, 291]. 
Adverse Events 
 The safety of intrathecal neostigmine has been examined 
systematically in rats after multiple bolus deliveries and after 
chronic infusion in the dog [292] and no apparent tissue 
toxicity was noted. In humans, intrathecal neostigmine has 
been shown to provoke nausea and vomiting [277]. 
Future Directions 
 Considerable work has focused on the development of 
novel muscarinic agonists and cholinesterase inhibitors 
[293]. As noted above, there is considerable evidence that 
subtypes of muscarinic receptors may be involved in the 




 Delivery of adenosine and associated ligands can have 
potent antihyperalgesic effects in models of acute nociceptive 
processing [294], neuropathy [294-298] and inflammatory 
pain [299]. In humans, intrathecal adenosine has been shown 
to reduce allodynia in experimental pain models [300, 301] 
and in patients with neuropathic pain [302,303]. Negative 
results with intrathecal adenosine have also been reported 
[304]. 
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Mechanisms 
 Adenosine can activate four G-protein-coupled receptors: 
A1, A2A, A2B, A3 [305]. A1receptors are expressed on small-
to-medium-diameter neurons of the DRG and on dorsal horn 
neurons [306-309] and serve to inhibit synaptic transmission 
through presynaptic inhibition of neurotransmitter release 
and on postsynaptic inhibition of excitatory transmission 
[309, 310]. 
Adverse Events 
 In preclinical studies, A1, agonists and A2A antagonists 
reversibly depressed the volume-evoked micturition reflex 
[311, 312] and produced motor weakness. An unexpected 
observation was that chronic exposure of spinal systems to 
A1agonists led to a hyperalgesic state [313]. The safety of 
intrathecal adenosine has been examined systematically in 
rats after multiple bolus deliveries and after chronic infusion 
in the dog [300, 314] with no adverse signs or 
histopathology. Studies with intrathecal delivery of the A1 
agonistR-phenylisopropyl adenosine (R-PIA) also failed to 
show histopathology [315]. 
Future Directions 
 It has been reported that A2Areceptor agonists may 
produce a long-term reversal of allodynia in mononeuro- 
pathies [316]. It has been proposed that the mechanisms of 
this long-term effect may reflect the effects ofA2Aagonists as 
potential glial inhibitors. The complexity of this possible 
drug effect is also reflected by the observation that 
A2Areceptors may serve to stimulate glutamate release and 
that A2Aantagonists may have protective effects by reducing 
that excitatory effect [317]. 
Cyclooxygenase Inhibitors 
Cyclooxygenase Inhibitors 
 Considerable work has shown that in the face of 
persistent small afferent input there is an increase in the 
release of cyclooxygenase products such as PGE2 [318-320]. 
This increase results from activity in constitutively 
expressedCOX-2 in spinal dorsal horn neurons and glia 
[321]. The role of these PGs in the development of a 
sensitized dorsal horn state of processing is mediated by 
several mechanisms including enhanced opening of voltage-
gated calcium channels [322] and the loss of intrinsic 
inhibition by an inhibitory effect upon dorsal horn glycine 
receptor function [323]. Intrathecal delivery of COX-1/2 or 
COX-2 selective inhibitors has been shown to have 
antihyperalgesic effects in a variety of models producing 
central sensitization [318, 324-326]. Spinal COX-1 inhibition 
has attenuating effects upon postoperative pain [327] and 
Ketorolac is a mixed COX-1/2 inhibitor. Preclinical work 
has shown no evidence of toxicity in repeated bolus 
injections in the rat and continuous intrathecal infusion in the 
dog [328, 329] and was well tolerated in humans [330]. In 
human studies, intrathecal ketorolac delivered as a bolus had 
modest effects in human experimental pain models [331], 
enhanced morphine analgesia after total knee replacement 
[332], but had no effects on postoperative pain [333] or hip 
arthroplasty [334]. 
Other Potential Pharmacological Spinal Targets 
 In this section, we will briefly consider the role of several 
pharmacological targets that have been shown to play a role 
in spinal nociceptive processing. It should be stressed that 
virtually all of the mechanistic studies defining pain 
processing have shown the importance of spinal systems. 
Accordingly, future pharmaceutical targets may likely arise 
from one or more of systems that have been shown to have 
actions on the behaviorally defined pain end point after 
intrathecal delivery in one of more preclinical models (see 
[10-11]). Several of these will be summarized below. 
Importantly, most of these agents and their associated targets 
have not undergone any systematic assessments of toxicity 
and may carry with them unexpected/off-target membrane 
effects. 
Metabotrophic Glutamate Receptors (mGluR) 
 Eight mGluRs (mGluR1-8) have been identified and 
these are divided into three groups [335]: Group I (mGluR1 
and mGluR5) stimulates phospholipase C (PLC); Group II 
(mGluR2 and mGluR3) and Group III (mGluR4 - mGluR8) 
inhibit adenylate cyclase [335, 336]. In the brain and spinal 
cord, nGluRs have been identified on primary afferents, 
neurons and glia [337, 338]. Group I is localized 
postsynaptically, whereas Group II and Group III are present 
largely on the presynaptic terminal [339]. Activation of 
Group I mGluRs have been implicated in the processes of 
central sensitization and persistent nociception, whereas 
activation of Group II mGluRs has been shown to suppress 
facilitated states [340]. Accordingly, antagonists of Group I 
mGluRs and agonists of Groups II and III mGluRs have 
shown analgesic activity in neuropathic or inflammatory 
pain states [341-348] and accordingly represent a promising 
target for the development of future spinally-targeted agents 
[349, 350].  
Toll Receptors 
 Toll-like receptors (TLRs) are a family of pattern 
recognition receptors that recognize a variety of injury-
associated molecular structures. They are located on 
neuronal and non-neuronal cells in the spinal cord and signal 
through downstream pathways that often lead to anelaboration 
of a variety of proalgesic/inflammatory cytokines(DRG) 
[351, 352]. Intrathecal delivery of TLR4 antagonists has 
been shown to have ameliorating effects upon inflammatory 
and neuropathic pain states [353] and has been implicated in 
the phenomena of opiate-induced hyperalgesia [354]. Novel 
structures for blocking TLR activation through an interaction 
with the TLR4 ligand or targeting downstream signaling 
have been of therapeutic interest [355-357]. 
Cannabinoids 
 Cannabinoid receptors (CB1r and CB2r) are 7 trans- 
membrane, G-protein- coupled receptors that negatively 
couple through Gi/o proteins [358]. Spinally, CB1 receptors 
are expressed in neurons while CB2 receptors are expressed 
on microglia, where the CB1 agonists reduce excitatory 
transmitter release and CB2 receptors attenuate microglial 
activation [359, 360]. Intrathecal delivery of both CB1 and 
CB2 preferring ligands reduced facilitated states such as the 
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formalin model, hyperpathia in neuropathy models and in 
tumor bone pain in rodents [361-363]. As many of these 
ligands have very high cLogPs, appropriate formulation in 
spinally compatible vehicles is an important consideration in 
their development for spinal use. 
Purine Agonist/Antagonists 
 Adenosine triphosphate is widely released in the nervous 
system [364] and has been shown to interact with the P2 
receptor family, which is divided into P2X ligand-gated 
ionotropic receptors (further divided into 7 subtypes) and 
P2Y\G-protein-coupled receptors divided into 8 subtypes). 
The P2Y receptors may couple through either Gq/G11 to 
activate the phospholipase C/inositol triphosphate (InsP3) 
endoplasmic reticulum Ca
2+
-release pathway (the P2Y1, 
P2Y2, P2Y4, P2Y6, and P2Y11 receptors) or through to Gi/o, 
which inhibits adenylyl cyclase and serves to modulate ion 
channel function [365]. Both P2X and P2Y receptors are 
widely distributed in spinal dorsal root ganglia and in spinal 
neurons and glia [366]. A large persuasive literature has 
implicated these receptors as primary activators of glia, 
particularly microglia, leading to the spinal release of a 
plethora of proinflammatory proteins and cytokines relevant 
to initiating facilitated pain states [367-371]. Intrathecal 
delivery of a variety of P2X and P2Y inhibitors results in a 
temporary reversal of hyperpathia after nerve injury [372-
375]. Studies with a variety of approaches have strongly 
implicated the P2X4 subtype in spinal facilitation initiated 
by tissue and nerve injury [376]. Intrathecal administration 
of a P2X4R antisense oligodeoxynucleotide prevented the 
increase in P2X4R protein expression and suppressed the 
development of mechanical allodynia [372]. 
Anti-Inflammatory Cytokines (IL-10) 
 Activation of a variety of glial signaling cascades will 
lead to the release of a variety of cytokines including 
activation of NF-B and results in the production of 
proinflammatory mediators such as TNF, IL-6, and IL-1β 
that activate pro-algesic cascades [377]. Conversely, these 
cascades can lead to the release of so-called anti-inflammatory 
products that may bind the soluble product (IL-1ra) and 
cytokines such as, IL-4, IL-6, IL-10, IL-11, IL-13, TGF-β, and 
various soluble cytokine receptors [378], which can regulate 
the inflammatory cascade [379]. As an example, intrathecal 
delivery of IL-10 has been shown in animal models to have 
therapeutic efficacy in a variety of pain models [380]. 
Future Targeting 
 An exciting component of pain modulation has been the 
implementation of several novel approaches to modify the 
function of systems that process nociceptive information. A 
brief note on these approaches will be given below. 
Targeted Toxins 
 This approach takes advantage of toxin delivery to 
specific cell systems. Several examples can be considered. 
TRPV1 Receptors 
 These TRPV1 channels are present on the terminals of 
small high threshold primary afferents and when activated by 
ligands such as capsaicin [381] and analogues [382] will 
yield activation, desensitization and loss of terminals 
expressing the channel after spinal delivery [383]. Intrathecal 
resiniferatoxin, a potent TRPV1 agonist, has been shown to 
have a potent antihyperalgesic effect in canine persistent 
pain models [384] and is currently in human clinical trials 
(http://clinicaltrials.gov/show/NCT00804154). A further modality 
for targeting TRPV1- bearing neurons takes advantage of the 
fact that when activated TRPV1 forms a pore that is able to 
pass large charged molecules. Protonated local anesthetics 
(e.g., QX314), which cannot normally enter the axon, can 
pass through TRPV1 channels that have been opened by 
TRPV1 agonists such as capsaicin and produce a selective 
block of sodium channel function in the TRPV1 (+) afferent 
axon [385]. 
Toxins Coupled to Agonists for G-Protein-Coupled 
Receptors 
 G-protein-coupled receptors when occupied by their 
agonists will undergo internalization [386]. Composite 
molecules composed of the ligand and a toxin will bind to 
the respective GPCR. Such binding leads to an 
internalization of the agonists and the coupled toxin into the 
cell expressing the particular receptors [387]. Such GPCRs 
thus far intensely studied include those for the neurokinin 1 
for sP. These receptors are present on cells within the spinal 
pain pathway. The spinal neurokinin 1 receptor is located on 
postsynaptic second order neurons [388]. The majority of 
work at present has focused on the NK1-r. However, other 
G-protein receptors that are likely ligands are the mu 
receptors. As reviewed above, mu opiate receptors located in 
the spinal cord are primarily located in Laminae I and II on 
the nerve terminals of primary afferent C-fibers and 
interneurons in Lamina II. Agonist binding to these receptors 
leads to their internalization [19].  
 i) Saporin, a protein derived from the plant Saponaria 
officinalis, has been coupled to a variety of ligands including 
dermorphin, a ligand for the mu opiate receptor, and sP, the 
ligand for the neurokinin 1 receptor. The internalized saporin 
is cleaved in endosomes within the cell and serves to block 
ribosylation thereby preventing protein synthesis and leading 
to death of the targeted cells. Intrathecal sP-saporin has been 
shown to lead to a robust change in a variety of pain states in 
several species including the rodent [389] and dog [261]. 
Large animal safety studies have shown target engagement 
after intrathecal delivery showing local knockdown of spinal 
NK1-r protein and message [390]. Importantly, at high 
concentrations motor dysfunction was observed that 
reflected upon the presence of NK1-r in motor neurons in the 
dog. Intrathecal sP-Saporin is currently in human clinical 
trials (http://clinicaltrials.gov/show/NCT02036281). 
 ii) Botulinum toxin. Botulinum toxin is constructed of a 
heavy chain (HC) and a light chain (LC). The HC enables 
the uptake of the complex into the cell. Once in the cell, the 
complex is cleaved freeing the LC, which is the active 
enzyme cleaving SNARES [391]. SNAREs play an 
important role in mobilizing vesicles for transmitter release 
and in enabling movement of certain proteins to the 
membrane, such as the GLUA1 AMPA receptor subunits 
[392]. By cleaving SNAREs, transmitter release is blocked 
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and intracellular trafficking may be diminished. Intrathecal 
BoNTs have been shown to produce antihyperalgesic effects 
in a number of preclinical models of inflammatory and 
neuropathic hyperpathia [393-396]. The BoNT uptake is 
considered to be ubiquitous and the potent effects upon 
transmitter release may include inhibitory interneurons and 
motor neurons [397, 398]. A single human experience has 
emphasized the potential of producing an enhanced pain 
state, perhaps through block of inhibitory amino acid release 
[399]. An approach to achieving specificity has employed 
the GPCR coupling motif described above. Here sP coupled 
to the LC may be delivered IT and the coupled molecule 
uptake is restricted to cells that express the NK1 receptor 
[400]. Such an approach is reversible and may find utility in 
long-lasting but non-terminal pathophysiological pain states. 
Gene-Based Approaches 
 Targeting specific proteins that play a role in nociceptive 
processing has been accomplished with several methodologies 
including intrathecally-delivered antisense and viral and 
nonviral transfection [401-403]. 
 i) Intrathecal antisense has been employed to reduce 
expression of a variety of proalgesic mediators, including 
growth factor cellular matrix proteins (thrombospondin) 
[404] and receptors relevant to nociceptive processing, 
including the NK1 receptor for substance P [405], purines 
[372]; GFRα1, receptor for GDNF [406], NMDA receptors 
[407]; glutamate metabotrophic receptors [408-410], P2X3 
[411, 412], TrpV1 receptors [413], TrpV1 receptors [413], 
CCR2 (canonical receptor for MCP-1) [414], synaptic 
scaffolding proteins [415], a variety of kinases such as P38 
MAPK [416, 417], phospholipases [418], and a variety of 
channels including sodium (Nav1.8: [419, 420] and calcium 
channels (T-type: [421, 422]). Inactivating transcription 
factors by employing an oligonucleotide decoy protein 
represents an alternate approach to prevent activation 
otherwise initiated by a pain state [423]. 
 ii) Transfection by intrathecal delivery of viral vectors 
encoding a given protein or the use of nonviral methods  
such as nanoparticles or permeabilizing systems [403] can 
enhance the targeted protein expression in vivo. Several 
examples may be noted. i) Dorsal root ganglion neurons 
virally transduced with a vector coding for glutamic acid 
decarboxylase (QHGAD67) increase the release of spinal 
GABA to produce an analgesic effect [424-425]. ii) Animals 
displayed increased expression of endomorphin-2, an opioid 
peptide [426], or the preprohormone for enkephalin [427] or 
ß endorphin [428] after intrathecal vector transfection 
elevated thresholds. iii) The use of intrathecal viral vectors 
or plasmid delivery to increase appropriate antihyperalgesic 
targets has been shown to have utility. Thus, increased spinal 
expression of IL-10 (anti-inflammatory cytokine)or plasmid 
delivery was anti-hyperalgesic [424, 429-431]. Increasing 
MAPK (Mitogen activated protein kinase) phosphatase-1 
reduces activation of P38 MAPKs and this resulted in 
reduced nerve injury-evoked increases in inflammatory 
cytokines and chemokines and hyperalgesia [432]. Increased 
expression of the Ca
2+
 channel-binding domain 3 (CBD3) 
peptide blocks function of Ntype calcium channels and block 
nerve injury-induced hyperpathia [433]. Increased expression 
of the potassium channel Kv1.2 reduced nerve injury-
induced hyperpathia [434]. Transfecting small interfering 
RNAs can be used to reduce Nav1.7RNA and protein in 
DRG and reduce hyperpathia in diabetic rats [435]. An 
important issue is the ability of various viral vectors to 
transefect dorsal root ganglion cells vs.spinal parencyhma. 
After intrathecal delivery, DRG neurons are readily 
transfected wheras the transfection of spinal neurons appears 
restricted at best [436]. Issues related to the ability of viral 
particles to move into the parechnyma have been consideredas 
well as the use of direct intraparenchymal injections [437]. 
Here the potential role of the pia mater in establishing such a 
barrier to particulates and larger molecules in the CSF has 
been noted in humans and dogs [438-440]. Techniques to 
increasethat movement have been proposed,including the use 
of hypertonic solutions [441]. 
Future Issues of Intrathecal Delivery 
Intrathecal Drug Distribution 
 The effect of intrathecal local anesthetics upon sensory 
input reflects their interaction with sodium channels on the 
sensory root (or upon superficial long tracts). Other agents 
exerting their action at specific receptors or certain channels, 
such as those for the mu opiate, GABA-B agonist, the N-
type calcium channel, or agents such as substance P saporin 
targeting NK1 receptor-bearing cell bodies, must reach the 
appropriate sites to regulate the input from the root 
innervating a given dermatome. This required targeting 
poses several issues. 1) As reviewed above, these targeted 
sites lie largely on the terminal of the primary afferent and/or 
upon cells postsynaptic to the afferent input. Accordingly, at 
the least, we can appreciate that if these agents remain in the 
intrathecal sac, they, unlike local anesthetics, have an action 
upon coupled receptors that are present on the terminals of 
the axon or postsynaptic neurons. 2) Pain arising from a 
specific dermatome, myotome or sclerotome reflects afferent 
input from defined dorsal root ganglion cells. Importantly, 
after entry into the dorsal horn, the sensory afferent axon 
sends collaterals rostrally and caudally as far as 4-6 spinal 
segments [442, 443]. Thus, current thinking is that the input 
arising from any given dermatome represents an excitatory 
drive that is mediated in the dorsal horn not just at the spinal 
segment of entry, but also at levels up to several spinal 
segments in distance.3) Terminals of small sensory axons lie 
within the parenchyma (substantia gelatinosa) at depths 
ranging from 10-20µ (mouse and rat) to 200-300 mu in the 
dog and 500 mu in humans. Intrathecal (superficially 
applied) agents must diffuse into the parenchyma to reach 
these target sites. As diffusion from the surface to the 
presumed site of action is a time-dependent process that is 
proportional to distance, it is interesting to note that all 
things being equal for a given drug such as morphine, the 
time of onset is fastest in the mouse (2-3min) [444] and 
proportionally more delayed in larger animals (30 min in cat 
and dog) [445-447] to >1 hr in humans [448, 449]. 
Importantly, several variables define the ability of a drug to 
diffuse into tissue. Further, movement through lipid rich 
tissues is delayed for agents with low logP than for those 
with higher values. Thus, recording from deep dorsal horn 
(Lamina V) neurons in cat spinal dorsal horn, it was 
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demonstrated that time to onset of suppression of cell 
activity was greatest from morphine and least for fentanyl 
[450, 451], a finding that corresponds to the behavioral time 
course effects of these agents in preclinical models [446, 
447] and clinical experience [452]. A second variable 
reflects on the pathways for extracellular drug movement, 
referred to as tortuosity and based on diffusional studies. 
Large molecules typically display a more restricted 
movement than small molecules [453, 454]. 
 Accordingly, it is believed that for these membrane-
targeted agents to produce a change in spinal nociceptive 
processing generated by a peripheral stimulus or spasticity, 
the intrathecally infused drug must move rostrally and 
caudally a distance of several segments and must then 
diffuse into the parenchyma to reach the membrane targets. 
Modeling of the CSF space has emphasized that spinal CSF 
does not undergo major flow [455, 456] and, thus, intrathecal 
agents delivered at a low rate, such as 10-20 µL/hr (as 
required by implanted pumps of limited reservoir volumes), 
undergo limited redistribution. This limited redistribution of 
low volume infusions has been emphasized in large animal 
models [38, 457-459] and to some degree inhumans [460]. 
Drug Dosing 
 A consequence of the intrinsically poor intrathecal 
redistribution of low volume injectates is the need to 
increase drug concentration to drive rostrocaudal movement. 
This use of high concentrations in human pumps has led to 
local toxicity. For opiates, the manifestation of this toxicity 
is the intrathecal granuloma [37, 116, 461-463]. Our group 
showed that the primary determinant for intrathecal opiate 
granulomas is the local concentration to which the tissue 
adjacent to the catheter tip is exposed [49, 51, 52]. Even 
baclofen, which has no strong evidence of granuloma 
formation in humans, may have limitations in that regard  
if concentrations higher than the currently available 
formulation (2mg/mL) is employed ([464] but see [267]). 
Formulation 
 An important issue characteristic for neuraxial delivery 
are the formulation requirements. Typically, neuraxial 
formulations are water-based products with a pH between  
5-7 and osmolarity in the range of 300 mOsM with minimal 
adjuvants (e.g., surfactants, antioxidants or antimicrobial 
constituents) (see: [465, 466]). Few are generally regarded as 
safe vehicles. Surfactant/detergents (Tween, polyethylene glycol) 
or common solubilizing agents such as dimethylformamide 
or dimethylsulfoxide cannot be routinely considered as 
“safe” and evaluation of the safety of a spinal therapeutic 
employing such products must consider the potential  
direct tissue effects of the formulation at the specific 
concentrations being employed. It should also be appreciated 
that DMSO and other solvents can interact and solubilize 
various plastic-based hardware (e.g. catheters, syringes, 
tubing and plastics) used to administer the drug. The family 
of cyclodextrins has been widely employed preclinically  
for producing increased solubility and altered distribution  
of otherwise water insoluble agents [467-470]. Other 
formulation strategies, including liposome, microsphere and  
 
nanoparticle compounds, to enhance the duration of action 
and reduce peak concentrations of intrathecally-delivered 
agents have been proposed to permit single long-lasting drug 
delivery paradigms. Such systems have been described in ex 
vivo and in vivo work for baclofen [471, 472] (see [466] for 
review). 
Infusate Delivery Profile 
 Enhancement of redistribution may minimize the risk of 
local intrathecal drug concentration-based toxicity. Strategies 
for enhancing redistribution and, accordingly, reducing the 
concentration at the catheter tip can been proposed. A 
solution to this issue by changing delivery of the total daily 
infused to multiple bolus dosing may enhance the efficacy 
and reduce the potential toxicity associated with intrathecal 
therapeutics. In previous work in the dog, continuous 
delivery of a given dose of morphine at a high concentration 
yielded granulomas. Continuous infusion of the same dose at 
a lower concentration did not result in a granuloma [51]. 
Daily bolus delivery of the same total dose of morphine had 
no effect [49, 447]. Other strategies that may possess at least 
theoretical interest is the use of repetitive microboluses 
instead of a truly continuous infusion and the use of 
multiport small orifice catheters that would evenly distribute 
injectate over the length of the catheter rather than from a 
single port at the catheter tip. 
Device Compatibility 
 Implantable pumps require appropriate solution stability 
for the 4-6 weeks the pump is delivering. Stability of the 
solutions at body temperature and in the pump reservoir 
must be defined in the course of drug development. Further, 
formulations for continuous infusion require delivery by 
existing pump systems. High concentration solutions, extreme 
pH (e.g.,<3) and formulations or drug combinations may 
exert effects upon pumping mechanisms. Each manufacturer 
may have compatibility protocols that require consideration 
for drugs to be delivered by such devices and literature exists 
for some agents and agent combinations (see, for example: 
[473, 474]. Given the different mechanics of each pump 
(e.g., valved vs. peristaltic), compatibility in one pumping 
system dose not guarantee compatibility in another. 
Preclinical Assessments in Spinal Analgesic Drug 
Development 
 The rodent models have been useful in defining the 
pharmacology of spinal nociceptive processing. As noted 
above, however, the use of neuraxial drug delivery poses 
issues related to scaling of the volumes and kinetics of the 
intrathecal space. The issue of whether an intrathecal 
molecule can make its way to the target site in the 
parenchyma of humans is not readily defined in the much 
smaller rodent cords. This raises the need to define effects 
upon behavior and target engagement in a large spinal cord. 
Further, the FDA requirements for a drug progressing to 
approval mandates safety to be demonstrated in a large 
animal preclinical model in addition to small animal (rodent) 
models. Particularly with regard to pharmacokinetic profiles, 
large animal models such as dogs, sheep, and primates  
offer similar metabolic functions [458, 475]. Experimental  
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threshold models have been described for these species (see, 
for example, in dog [476-478] and in sheep [479, 480]. Such 
models, while useful, may not capture the complexities of 
the inflammatory/nerve injury pain states. Models of 
experimental injury such as joint injury in models of 
osteoarthritis are well described [481-485]. Of particular 
interest has been the growing implementation of clinical 
studies in companion animals and sheep suffering from 
natural pathologic processes accompanied by a pain 
condition. Such conditions in dogs include fore and hind 
limb osteosarcoma and osteoarthritis [486] and osteosarcoma 
[487]. Numerous scoring systems and scales are available for 
assessment of pain in animals, which range from simple 
descriptive scales, visual analogue scales, subjective verbal 
scales, numeric rating scale, and composite pain scales. 
Owner-completed questionnaires have been validated to 
assess the severity and impact of chronic pain syndromes in 
dogs with bone cancer and osteoarthritis [488]. Such 
inventories have been shown to be useful in defining the 
efficacy of a variety of spinal and [261, 384] systemic [489] 
therapies (see [490]. Strengths of such tools include its 
incorporation of animal behavior over a period of time as 
opposed to assessment once under the influence of an 
abnormal environment. Appropriate study design is essential 
in preclinical therapeutic assessment to ensure studies are 
carried out in a humane fashion with the effort to minimize 
the severity and duration of pain to that which is necessary 
for the information sought. Appropriate rescue therapeutics 
are incorporated into the study design as in human clinical 
trials to provide pre-emptive analgesia when at all possible, 
analgesia once the study endpoint is met or to provide rescue 
analgesia if pain is beyond the acceptable severity as 
determined by the study guidelines when pain is sustained in 
a study.   
Intrathecal Drug Safety Evaluation 
 A final issue to consider in developing a spinal agent is 
the need for specific preclinical safety evaluations 
employing this route of delivery. Issues of such safety 
evaluations have been extensively discussed [243, 244, 462, 
491]. Several specific guidelines will be outlined here. 
 i) At a minimum, drugs for neuraxial delivery must 
undergo preclinical safety assessments for the appropriate 
route (epidural/intrathecal) with the delivery motif proposed 
(e.g., bolus vs. continuous infusion) in functionally relevant 
large animal models (dog, sheep, primate), which have been 
shown to display drug responses in previous work. The use 
of large animals vs. small animals (e.g., rodent) reflects upon 
the issue of scaling of intrathecal volumes and kinetics 
across species particularly at the extremes. 
 ii) Study design must incorporate drug concentrations 
that meet or exceed those to be developed for human use and 
employ the respective formulation proposed for approval. 
Where feasible, the drug dosing should be shown to have 
appropriate target engagement (e.g., behavioral endpoints, 
CSF concentrations, and knock-out of target marker (e.g., 
receptor or enzyme protein). The development of such data 
is important not only because it demonstrates confirmatory 
effects in another species, it has the practical benefit of being 
able to show the safety data studies to be constructed so as to 
define safety as multiples of a therapeutically effective dose 
in a large spinal cord (see, for example [390]). 
 iii) In the development of chronically delivered agents, 
the minimum length of exposure profiles should be 1-3 
months to ensure that long-term safety is demonstrated. 
 iv) Systemic safety must also be demonstrated for drugs 
or compounds administered spinally. Neuraxially delivered 
drugs undergo local distribution into the CSF. Flow patterns 
are largely influenced by respiratory and cardiovascular 
cycles (respirations and pulsations, respectively) with drug 
uptake into spinal cord tissue or into the meninges ultimately 
occurring. Elimination of spinally-administered drugs 
eventually occurs through the systemic circulation, thus 
systemic effects and plasma concentrations must be 
measured to demonstrate systemic safety. 
 v) The principle characteristic separating pharmacological 
investigation from one defining safety study is the 
implementation of systematic histopathology of the target 
tissues (see [492]). An important implication of the above 
commentary is that because of the peculiar nature of the 
intrathecal space as regards local and persistent exposure is 
that changes in drug delivery profile (bolus vs. infusion), 
volume or rate of drug delivery and most certainly formulation 
(pH/osmolarity/ionic or additive content) and most certainly 
concentration must be considered as defining variables for 
the characterization of potential toxicity. Our experience 
with alterations in these variables for intrathecally delivered 
drugs (e.g., opiates and local anesthetics) emphasizes that 
such changes can have clear impacts upon the assertion of 
safety of the formulation. 
 vi) Adult versus neonate. Finally, it has long been 
appreciated that neuraxial anesthesia and pain management 
therapies are relevant to the neonatal and pediatric population. 
The current concerns over the effects of general anesthetics 
on neural development in the young population has increased 
the focus on the neuraxial route. Yet, there has been a 
paucity of data to indicate the relative safety of neuraxial 
anesthetics in the same population (see [196, 493-496]. Given 
issues of pathway development and synaptic connectivity, 
assessment of the effects of neuraxial agents on concurrent 
and future spinal function must be considered in further 
application of analgesics and analgesic agents to this space 
[491]. 
SUMMARY 
 In summary, the spinal delivery of therapeutic  
agents reflects upon the role played by the spinal cord in a 
number of sensory and motor functions and the diverse 
pharmacological components that are associated with these 
systems. The initial demonstration of spinal catheterization 
in the rodent provided a robust model to assess the effects of 
drugs with an action limited to the spinal cord on behavioral 
function [497, 498]. The robust and selective effects of 
spinal opiates on pain behavior first shown in this rodent 
model (and the growing understanding of the complex 
algorithms that encode the input-output relationships in the 
spinal dorsal horn has resulted in exciting advances in the 
management of these adverse sensations, which, upon arrival 
at higher centers, initiate the pain experience. 
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